Drugs / DTaP-IPV-HB-Hib vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03547271 | Dec 2018 → May 2023 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV-HB-Hib vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547271 ↗ |
| Modality | Vaccine | “hexavalent vaccine (combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and haemophilus influenzae type b conjugate vaccine [DTaP-IPV-HB-Hib]” NCT03547271 ↗ |